Salarius Pharmaceuticals (NASDAQ:SLRX) Announces Earnings Results

Salarius Pharmaceuticals (NASDAQ:SLRX) released its earnings results on Friday. The company reported ($0.66) EPS for the quarter, Zacks reports.

Salarius Pharmaceuticals Trading Up 6.4 %

Shares of NASDAQ:SLRX opened at $0.95 on Friday. The stock has a market capitalization of $1.65 million, a P/E ratio of -0.12 and a beta of 0.59. Salarius Pharmaceuticals has a 1-year low of $0.83 and a 1-year high of $7.20. The business has a 50-day moving average price of $1.72 and a two-hundred day moving average price of $1.61.

Salarius Pharmaceuticals Company Profile

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.